Henlius Biopharmaceuticals 02696K Entered into a Collaboration and License Agreement with PALLEON for E602 and Combination Therapies
1
1219
Today’s Focus
Henlius 02696K Enters into Collaboration and License Agreement with PALLEON for E602 and Combination Therapies
Fuhong Hanlin 02696K announced that the company has entered into a cooperation greece phone number list and license agreement with Palleon Pharmaceuticals Inc. Palleon on December 19, , pursuant to which the two parties agreed to make agreements on the global cooperative development of E602 and combination therapies for the treatment of human diseases and their commercialization in their respective licensed territories.
Palleon will grant the Company an exclusive license to develop, use, produce, commission production, supply, sell, offer for sale, import, handle regulatory affairs, apply for marketing authorizations and commercialize licensed products in the field and the Company's licensed territory based on Palleon's proprietary technology and patents.
The Company will grant Palleon an exclusive license to develop, use, manufacture, commission manufacture, supply, sell, offer for sale, import, handle regulatory affairs and commercialize licensed products based on the Company's proprietary technologies and patents in the field and Palleon's licensed territory.